Baseline results of the Neuro<scp>NEXT</scp> spinal muscular atrophy infant biomarker study

Abstract

By the time infants were recruited and presented for the baseline visit, SMA infants had reduced motor function compared to controls. Ulnar CMAP, EIM, blood SMN mRNA levels, and serum protein analytes were able to distinguish between cohorts at the enrollment visit.